Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Tergene Biotech Pvt Ltd

    Tergene Biotech Pvt Ltd, is a biotech company engaged in production of human biologics for novel vaccines and antibody drug conjugates. The company has successfully developed te

  • No Image
    Teva Pharma India Pvt Ltd

    Teva Pharma India (TAPI) is the leading international supplier of active pharmaceutical ingredients (APIs). It has broadest portfolio of over 300 API products, TAPI achieved thi

  • No Image
    Themis Medicare Ltd

    Themis Medicare Ltd was promoted by Mr. Shantibhai D. Patel, a pioneer in Indian Pharmaceuticals Business.

    It is a joint venture pharmaceutical company, with Gedeon Ric

  • No Image
    Thinq Pharma cro Ltd

    THINQ Pharma is an integrated pharmaceutical company with broad global presence and world class products and services. The company is head quartered in Singapore and has a fully